

Press Release

ChromaCon's CaptureSMB process has successfully been scaled from laboratory to pilot and production scales.

Zurich, Switzerland, February 13, 2018.

A significant milestone has been achieved in scaling up the CaptureSMB process, an optimized two-column periodic countercurrent capture process for the purification of monoclonal antibodies from laboratory scale to industrial pilot and production scale.

A team from Bristol-Myers Squibb (Devens, MA), ChromaCon (Zurich) and LEWA (Devens, MA) reports in an article in *BioProcess International* (online February 2018, print April 2018) about the *Scale-Up of Twin-Column Periodic Counter-Current Chromatography* (link below). The article shows the seamless transfer of a laboratory-scale CaptureSMB process to pilot/process scale, achieving excellent results.

The lab-scale experiments were run on a Contichrom CUBE Combined (ChromaCon). The results from these experiments were excellent predictors of the performance on the 100x greater pilot and production scale runs on an EcoPrime Twin system (LEWA). Compared to batch capture processes, a 2.5-fold higher productivity, an increase in resin utilization from 67% to 92%, and a 50% reduction in buffer consumption could be realized.

Thomas Müller-Späth, COO of ChromaCon and co-author of the study, commented: "The data clearly show the benefit of a twin-column continuous capture processes at production scale. The smooth and seamless upscaling process was facilitated by the low complexity of the twin-column CaptureSMB process. This is also an important factor when performing process validation and seeking regulatory approval."

Michael Bavand, CEO of ChromaCon commented: "The validation of the CaptureSMB process performance at industrial scale represents a significant milestone for the bioprocess industry. Together with our partners we pave the way for a fast adoption of continuous processes at industrial scale."

Link to article: <http://bpi.bioprocessintl.com/scale-up-of-twin-column-periodic-counter-current-chromatography-for-monoclonal-antibody-purification>.

About ChromaCon AG

ChromaCon AG is a private Life Science Tool company located in Zurich, Switzerland, providing best-in-class process solutions, dynamic process control and process simulation tools to the biopharmaceutical industry. ChromaCon has developed and patented novel continuous process principles and process control providing significant CAPEX and OPEX savings and enabling scalable chromatographic solutions for large scale



purification applications. Contichrom® laboratory-scale equipment are marketed worldwide by ChromaCon and its partners. ChromaCon has provided global licenses for continuous process technologies to LEWA for implementation into EcoPrime® Twin scale-up systems.

ChromaCon Contact

To find out more about ChromaCon please contact us directly or visit our website.

Dr. Michael Bavand, CEO, info@chromacon.com, www.chromacon.com